THYQUIDITY solution

THYQUIDITY is a liquid levothyroxine designed to deliver
individualized dosing for your patients

Broad dosing flexibility—liquid formulation enables you to prescribe the medically appropriate strength of levothyroxine necessary to manage your patients' hypothyroidism

BROAD DOSING flexibility

Liquid formulation enables you to prescribe the medically appropriate strength of levothyroxine necessary to manage your patients’ hypothyroidism1,*

Consistent daily dosing—no need for tablet splitting or irregular administration schedules to provide a dose that is in between commercially available tablet and capsule strengths

Consistent daily dosing

No need for tablet splitting or irregular administration schedules to provide a dose that is in between commercially available tablet and capsule strengths1

Bioequivalent to Synthroid®—THYQUIDITY (levothyroxine sodium) oral solution demonstrated bioequivalence to Synthroid in a single-dose crossover pharmacokinetic study. Please see full Prescribing Information Including Boxed Warning.

Bioequivalent to Synthroid®

THYQUIDITY demonstrated bioequivalence to Synthroid in a single-dose crossover pharmacokinetic study2

*Because THYQUIDITY dosing depends on a variety of factors, doses must be individualized. Doses >200 mcg/day are seldom required. An inadequate response to doses >300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors.

Not an actual patient.

THYQUIDITY offers broad dosing flexibility

Liquid THYQUIDITY allows you to prescribe an individualized dose to each patient,
enabling precise dose adjustments1

Liquid THYQUIDITY allows you to prescribe an individualized dose to each patient, enabling precise dose adjustments1

See how to convert mcg to mL to meet
your patients' unique treatment needs

dosing calculator
Some patients may benefit from additional dose options that are not currently on the market in fixed dosage forms

Some patients may benefit from additional dose options that are not currently on the market in fixed dosage forms3,7,8

THYQUIDITY (levothyroxine sodium) oral solution enables gradual dose adjustments. Please see full Prescribing Information Including Boxed Warning.

THYQUIDITY enables gradual dose adjustments1

The use of a calibrated oral syringe can help meet your patients' unique needs

The use of a calibrated oral syringe can help meet your patients’ unique needs1

THYQUIDITY offers an established safety profile1

Adverse reactions associated with THYQUIDITY are primarily those of hyperthyroidism due to therapeutic overdosage1:

General
Fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
Central nervous system
Headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
Musculoskeletal
Tremors, muscle weakness, muscle spasms
Cardiovascular
Palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
Respiratory
Dyspnea
Gastrointestinal
Diarrhea, vomiting, abdominal cramps, elevations in liver function tests
Dermatologic
Hair loss, flushing, rash
Endocrine
Decreased bone mineral density
Reproductive
Menstrual irregularities, impaired fertility

Because THYQUIDITY is a narrow therapeutic index drug, over- or undertreatment may have negative clinical consequences1

THYQUIDITY offers manufacturing quality and
dependability that you and your patients can trust

Vertice Specialty Group follows robust manufacturing standards

THYQUIDITY (levothyroxine sodium) oral solution meets the specifications for a narrow therapeutic index drug and the criteria for bioequivalence to Synthroid. Please see full Prescribing Information Including Boxed Warning.

Reliability

THYQUIDITY meets the specifications for a narrow therapeutic index drug and the criteria for bioequivalence to Synthroid1,2

Manufactured, processed, and packaged to meet FDA Current Good Manufacturing Practice (cGMP) standards. THYQUIDITY (levothyroxine sodium) oral solution is gluten-free, sulfur-free, and lactose free. Please see full Prescribing Information Including Boxed Warning.

Quality

Manufactured, processed, and packaged to meet FDA Current Good Manufacturing Practice (cGMP) standards. THYQUIDITY is gluten-free, sulfur-free, and lactose-free1,9

Vertice Specialty Group has a proven 20+ year track record of manufacturing FDA-approved liquid pharmaceutical products

Expertise

Vertice Specialty Group has a proven 20+ year track record of manufacturing FDA-approved liquid pharmaceutical products

Dosing and Administration

See how THYQUIDITY is designed to deliver an individualized dose to patients

INDICATION

Hypothyroidism

THYQUIDITY™ (levothyroxine sodium) oral solution is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid Stimulating Hormone, TSH) Suppression

THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Limitations of Use

THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, as there are no clinical benefits and over-treatment with THYQUIDITY may induce hyperthyroidism.

THYQUIDITY is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

IMPORTANT SAFETY INFORMATION

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

Please see full Prescribing Information including Boxed Warning.

You may report side effects to the FDA at 800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vertice Specialty Group at 800-470-6233 or email at medinfo.vertice@apcerls.com.

References: 1. THYQUIDITY (levothyroxine sodium) oral solution [package insert]. New Providence, NJ: Vertice Specialty Group: 12/2020. 2. Data on file, Vertice Specialty Group. Altasciences clinical study report. 3. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). 41st ed. US Department of Health and Human Services; 2021:3-261. 4. Synthroid® (levothyroxine sodium) tablets [package insert]. North Chicago, IL: AbbVie Inc; 2020. 5. Unithroid® (levothyroxine sodium) tablets [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; 2019. 6. Tirosint-SOL® (levothyroxine sodium) oral solution [package insert]. Parsippany, NJ: IBSA Pharma Inc; 2020. 7. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751. 8. Duntas LH, Jonklaas J. Levothyroxine dose adjustment to optimise therapy throughout a patient’s lifetime. Adv Ther. 2019;36(suppl 2):S30-S46. 9. Data on file, Vertice Specialty Group. Ingredient certificates.

Synthroid is a registered trademark of AbbVie, Inc. Unithroid is a registered trademark of Jerome Stevens Pharmaceuticals, Inc. Tirosint is a registered trademark of IBSA Institut Biochimique SA.

INDICATION

Hypothyroidism

THYQUIDITY™ (levothyroxine sodium) oral solution is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid Stimulating Hormone, TSH) Suppression

THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

IMPORTANT SAFETY INFORMATION

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

The information provided on this site is intended only
for healthcare professionals (HCPs) in the United States.

Are you an HCP?

YES NO Take me to information for patients and caregivers

Coming Soon